The global sclerotherapy market was valued at USD 880.8 Million in 2020 and is projected to grow at a CAGR of 6.3% during the forecast period. Factors driving the growth of the sclerotherapy market include escalating numbers of varicose veins, upward demand for minimally invasive processes and technological progressions concerning venous illnesses.
Sclerotherapy comprises injecting a chemical solution, into the varicose veins. Typically, this is mixed in a syringe with air to produce foam which permits just a little of the chemical to go much further. Favorably, this foam can be seen on ultrasound which is used in a number of patients to monitor the injection treatment. The chemical harms the injected veins much as heat from a laser would, leading to inflammation and then to their obliteration. Compression is applied after injection to encourage the collapsed vein walls to stick together. This may be with a support stocking alone or in combination with a bandage.
Regionally, North America accounted for the largest market share of the global sclerotherapy market attributable to existence of worldwide players. Leading players of the global sclerotherapy market include BTG, LGM Pharma, Merz Pharma, Kreussler, Troikaa, Bioniche Pharma Group Ltd., ChanganTianyu group, Omega Pharmaceuticals, Endo-Flex among others.
Sclerotherapy Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 1,424.5 Million|
|Growth Rate||CAGR of 6.3% during 2021-2028|
|Segment Covered||Agent, Type, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||BTG, LGM Pharma, Merz Pharma, Kreussler, Troikaa, Bioniche Pharma Group Ltd., ChanganTianyu group, Omega Pharmaceuticals, Endo-Flex among others.|
Key segments of the global sclerotherapy market
Agent Overview, 2018-2028 (USD Million)
- Chemical Irritants
- Osmotic Agents
Type Overview, 2018-2028 (USD Million)
- Ultrasound Sclerotherapy
- Liquid Sclerotherapy
- Foam Sclerotherapy
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa
Reasons for the study
- Shift towards less-invasive treatment procedures
- Availability of advanced varicose vein treatment devices
- Huge burden of varicose vein cases
What does the report include?
- The study on the global sclerotherapy market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of agent and type. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global sclerotherapy market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global sclerotherapy market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global sclerotherapy market
Treatment options for varicose veins include endovenous laser ablation, compression hosiery, radiofrequency ablation, subfascial endoscopic perforator surgery, conventional operation, and sclerotherapy. The sclerosants most frequently used worldwide comprise sodium tetradecyl sulphate, glycerin, morrhuate sodium, hypertonic saline and polidocanol. While sclerotherapy is normally considered safe, at hand are certain publications that expose the occurrence of grave antagonistic events of sclerotherapy and this hints to safety concerns. Physicians should be alert of the likely serious and even mortal adverse measures of sclerotherapy, notify patients consequently and be equipped for the suitable management of these hostile events. Forthcoming research efforts must emphasis not only on the expansion of sclerosant agents with improved safety profile but likewise more prominently on the understanding of the pathophysiology of venous hypertension and on the progress of substitute treatment modalities that target the etiology of venous hypertension.
On the basis of type, the market is segmented into ultrasound sclerotherapy, liquid sclerotherapy, and foam sclerotherapy. The liquid sclerotherapy segment dominated the market in 2020, while foam sclerotherapy segment is likely to show the highest CAGR over the forecast period. The method of generating foam from the chemicals used for sclerotherapy earns special mention. This procedure is gaining admiration and the physician could endorse this as the primary therapy or to aid with clearing bigger veins subsequent to a surgical therapy. Since the foam preserves better connection with the vein walls it lets the physician to treat larger veins more effectively. Usually a smaller quantity of the chemical is essential which might also reduce the hazard for complications. Preparation for foam sclerotherapy is similar as for all other methods of therapy. Impediments are alike the traditional sclerotherapy. Foam sclerotherapy can be a bit more throbbing than traditional sclerotherapy.
North America accounted for the largest share of the global sclerotherapy market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period. Varicose veins are a common condition in the United States, affecting up to 60% of all Americans. Women, especially older ones are more likely than men to have this problem. 20% to 25% of women and 10% to15% of men in the general population have visible varicose veins. For many people, varicose veins and spider veins are simply a cosmetic concern. Most varicose veins do not require medical treatment. For others, varicose veins can cause aching pain and discomfort. Sometimes the condition leads to more serious problems, and they may signal a higher risk of other disorders of the circulatory system. In some cases, the circulation maybe hindered enough to cause swelling of the foot and ankle, discomfort, a tingling sensation, or a feeling of heaviness.